What Innate Pharma’s Kempen conference participation reveals about its 2026 biotech strategy
Innate Pharma heads to Kempen as investors assess its oncology pipeline, partnering outlook, and next catalysts. Read the full analysis.
Pharma & Biotech
Pharma & Biotech
What the Agenus-MiNK Therapeutics combination reveals about the next phase of GI cancer immunotherapy
Agenus brings botensilimab, balstilimab, and agenT-797 to AACR 2026. Read why this refractory GEC update matters and what risks remain.
Pharma & Biotech
Alpha Cognition expands ALPHA-1062 into traumatic brain injury, but approval is still a distant goal
Alpha Cognition won a U.S. patent for ALPHA-1062 in TBI. Read why the IP matters, what it changes, and where the biggest risks still remain.
Pharma & Biotech
What Alto Neuroscience’s ALTO-101 setback reveals about the difficulty of treating cognitive impairment in schizophrenia
Alto Neuroscience’s ALTO-101 missed in Phase 2. Read what the setback means for schizophrenia cognition, partnering prospects, and ALTO-207 next.
Pharma & Biotech
Why Gilead’s Arcellx tender extension matters more for cell therapy execution than for deal timing
Gilead extended its Arcellx tender offer. Read why the move matters for anito-cel, oncology M&A, and cell therapy execution risk.
Pharma & Biotech
Plixorafenib breakthrough status raises the stakes for FORE Biotherapeutics in BRAF-mutant high-grade glioma
FORE Biotherapeutics won FDA breakthrough status for plixorafenib in high-grade glioma. Read what this changes and what risks still remain.
Pharma & Biotech
Can Calidi Biotherapeutics, Inc.’s RedTail platform solve the solid tumor T-cell engager problem?
Calidi Biotherapeutics, Inc. unveils new RedTail and TROP-2 data at AACR 2026. Read what this means for solid tumor immunotherapy and CLD-401 next.
Pharma & Biotech
What Ocugen, Inc.’s OCU410ST milestone means for the race to treat inherited retinal blindness
Discover what Ocugen, Inc.’s OCU410ST milestone means for the future of inherited retinal blindness treatment and the race toward first approval.
Pharma & Biotech
How Cogent Biosciences, Inc.’s bezuclastinib filing could redefine the second-line treatment paradigm in gastrointestinal stromal tumors
Cogent Biosciences files bezuclastinib NDA in second-line GIST. Explore what the PEAK data could change for clinicians, regulators, and investors.
Pharma & Biotech
What Certis Oncology Intelligence reveals about the next phase of AI in cancer R&D
Certis Oncology has launched a new AI platform for translational oncology. Read what it could change for cancer drug development.